Da Form 7415: Fill & Download for Free

The only FDA-approved medication for hair loss in women is topical Minoxidil.Many excellent studies support the use of Minoxidil in women with all types of hair loss. (1–6)The drug is recommended for twice daily usage as a 2% solution for women and has been shown to be effective at stopping hair loss in 60% of cases and evi­dence shows that use of topical minoxidil can improve the quality of life for those with Female Pattern Hair Loss.Excellent results can be achieved with consistent usage. Recently, one study showed that a 5% foam worked just as well, used once daily in women, as the 2% worked twice daily. (7)There also were fewer complaints about itching and dandruff. Many physicians already recommend using the 5% foam once daily at bedtime as a way to increase compliance and simplify the morning grooming routine. This has since prompted the FDA to approve a women’s 5% Rogaine foam formulation for once daily usage. The risk of hypertrichosis – hair growth in other areas of the body - should still be discussed as it has been reported in 8.9% of patients using this regimen.Some women of Middle Eastern or Hispanic ancestry, or those with polycystic ovary syndrome, may already suffer from significant hirsutism – which is hair growth on the face - and do not want to worsen it with topical minoxidil. Other women in their 50s or 60s do not wash their hair more often than once a week, and dislike the idea of putting a product on the scalp every day and then not washing it out until they return to the salon. These women can benefit from off-label options like birth control pills, spironolactone, or finasteride.Κωνσταντίνος Αναστασάκης MD, PhD, Χειρουργός Κεφαλής & Τραχήλου, Ωτορινολαρυγγολόγος, Διδάκτωρ Ιατρικής Σχολής Δημοκρίτειου Παν/μιου Θράκης1 DeVillez RL, Jacobs JP, Szpunar CA, Warner ML. Androgenetic alopecia in the female. Treatment with 2% topical minoxidil solution. Arch Dermatol. 1994 Mar;130(3):303-72 Jacobs JP, Szpunar CA, Warner ML. Use of Topical Minoxidil Therapy for Androgenetic Alopecia in Women. Int J Dermatol 1993 Oct;32(10):758-623 Trancik RJ, Strauss PC, Albert DG, Means LK. Comparison of 5% topical Minoxidil, ROGAINE Topical Solution 2% and placebo in the treatment of female androgenetic alopecia (Protocol M/7415/0009). Upjohn Technical Report 9153-94-006. Unpublished; October 14, 1994c4 Trancik RJ, Strauss PC, Albert DG, Means LK, Sheu WP. Efficacy comparison of 5% topical Minoxidil, ROGAINE Topical Solution 2% and placebo in the treatment of female androgenetic alopecia (Protocol M/7415/0286). Upjohn Technical Report 9153-94-003. Unpublished; October 14, 1994d5 Price VH, Menefee E. Quantitative estimation of hair growth. I. Androgenetic alopecia in women: effect of Minoxidil. J Invest Dermatol 1990 Dec;95(6):683-76 Whiting DA, Jacobson C. Treatment of female androgenetic alopecia with Minoxidil 2%. Int J Dermatol 1992 Nov;31(11):800-4 70 Lucky AW, Piacquadio DJ, Ditre CM, Dunlap F, Kantor I, Pandya AG, Savin RC, Tharp MD. A randomized, placebo-controlled trial of 5% and 2% topical Minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol. 2004 Apr;50(4):541-537 Blume-Peytavi U, Hillmann K, Dietz E, Canfield D, Garcia Bartels N. A randomized, single-blind trial of 5% minoxidil foam once daily versus 2%minoxidil solution twice daily in the treatment of androgenetic alopecia in women. J Am Acad Dermatol. 2011 Dec;65(6):1126-1134